176 related articles for article (PubMed ID: 10344219)
1. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.
Simmons SJ; Tjoa BA; Rogers M; Elgamal A; Kenny GM; Ragde H; Troychak MJ; Boynton AL; Murphy GP
Prostate; 1999 Jun; 39(4):291-7. PubMed ID: 10344219
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
4. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
5. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
6. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
7. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
Small EJ; Reese DM; Um B; Whisenant S; Dixon SC; Figg WD
Clin Cancer Res; 1999 Jul; 5(7):1738-44. PubMed ID: 10430077
[TBL] [Abstract][Full Text] [Related]
8. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
[TBL] [Abstract][Full Text] [Related]
9. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.
Wei XX; Chan S; Kwek S; Lewis J; Dao V; Zhang L; Cooperberg MR; Ryan CJ; Lin AM; Friedlander TW; Rini B; Kane C; Simko JP; Carroll PR; Small EJ; Fong L
Cancer Immunol Res; 2016 Nov; 4(11):948-958. PubMed ID: 27688020
[TBL] [Abstract][Full Text] [Related]
10. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
11. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF, and IL12.
Parney IF; Farr-Jones MA; Kane K; Chang LJ; Petruk KC
Can J Neurol Sci; 2002 Aug; 29(3):267-75. PubMed ID: 12195617
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
13. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Palma M; Hansson L; Mulder TA; Adamson L; Näsman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Österborg A; Mellstedt H
Eur J Haematol; 2018 Jul; 101(1):68-77. PubMed ID: 29569742
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Lechleider RJ; Arlen PM; Tsang KY; Steinberg SM; Yokokawa J; Cereda V; Camphausen K; Schlom J; Dahut WL; Gulley JL
Clin Cancer Res; 2008 Aug; 14(16):5284-91. PubMed ID: 18698048
[TBL] [Abstract][Full Text] [Related]
17. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
Clive KS; Tyler JA; Clifton GT; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2010 May; 9(5):519-25. PubMed ID: 20450326
[TBL] [Abstract][Full Text] [Related]
18. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
19. Clinical safety of a viral vector based prostate cancer vaccine strategy.
Arlen PM; Skarupa L; Pazdur M; Seetharam M; Tsang KY; Grosenbach DW; Feldman J; Poole DJ; Litzinger M; Steinberg SM; Jones E; Chen C; Marte J; Parnes H; Wright J; Dahut W; Schlom J; Gulley JL
J Urol; 2007 Oct; 178(4 Pt 1):1515-20. PubMed ID: 17707059
[TBL] [Abstract][Full Text] [Related]
20. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
